PRINSTON ANNOUNCES APPROVAL OF GENERIC DIOVAN-HCT® TABLETS FROM THE U.S. FOOD AND DRUG ADMINISTRATION
CRANBURY, NJ – February 15, 2016 – Prinston Pharmaceutical, Inc. is proud to announce that the U.S. Food and Drug Administration (FDA) has approved its generic equivalent of Diovan HCT®(Valsartan and Hydrochlorothiazide Tablets USP), 80 mg/12.5 mg, 160 mg/12.5 mg, 160 mg/25 mg, 320 mg/12.5 mg, and 320 mg/25 mg. The Company is preparing for commercialization of this product through Prinston's generic division, Solco Healthcare, LLC.
"We are pleased to receive FDA approval of generic valsartan and hydrochlorothiazide tablets, a product that was self-developed and manufactured in our parent company’s Linhai, China facility," said Jun Du, Prinston’s CEO. "With a pipeline of over 34 Abbreviated New Drug Applications (ANDAs) pending approval, we continue to strengthen our presence within the US generic market by providing high value medicines at affordable prices.”
According to IMS, the brand and generic sales of valsartan and hydrochlorothiazide tablets products were approximately $192.4 million in the US.
About Prinston Pharmaceutical, Inc. Prinston Pharmaceutical, Inc. is a fast growing, emerging global pharmaceutical company, located in Cranbury, New Jersey, USA. We are a fully integrated pharmaceutical company engaged in product development, product registration, manufacturing, marketing and sales of high quality affordable generic prescription products to our customers. Our highly experienced R&D team meets market needs through innovation, rapidly bringing high quality products to the US market, to help patients get the best pharmaceutical products at an affordable cost. We deliver and maintain the highest quality standard and integrity in all of our products, which are manufactured by the company or its partners around the world in world-class cGMP (current Good Manufacturing Practices) manufacturing facilities.Tweet